SRI Earns FDA Orphan Drug Designation for Pancreatic Cancer

SRI’s Targeted Antigen Loaded Liposomes — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation for PDAC by the US FDA.